AgingResearch.NewsJoin free

Cilengitide

Intervention

1 paper1 finding

PubChem 176873ChEBI 177833

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: Biotechnology and Biological Sciences Research Council and 3 more
  • Cells1

Outcomes

1

Senescence-associated secretory phenotype (SASP)

downin human cells1

1 study

  1. Cilengitide inhibits senescence-associated secretory phenotype (SASP) in human cells.

    “cilengitide, an αvβ3 antagonist, has the ability to block the senescence-associated secretory phenotype (SASP) without affecting proliferation”

    Cellswithout affecting proliferation

    Integrin Beta 3 Regulates Cellular Senescence by Activating the TGF-β Pathway

    Cell reports7 Mar 2017

More on Senescence-associated secretory phenotype (SASP)

Latest

Related